» Articles » PMID: 17533614

Optimized Production and Concentration of Lentiviral Vectors Containing Large Inserts

Overview
Journal J Gene Med
Date 2007 May 30
PMID 17533614
Citations 77
Authors
Affiliations
Soon will be listed here.
Abstract

Generation of high titer lentiviral stocks and efficient virus concentration are central to maximize the utility of lentiviral technology. Here we evaluate published protocols for lentivirus production on a range of transfer vectors differing in size (7.5-13.2 kb). We present a modified virus production protocol robustly yielding useful titers (up to 10(7)/ml) for a range of different transfer vectors containing packaging inserts up to 7.5 kb. Moreover, we find that virus recovery after concentration by ultracentrifugation depends on the size of the packaged inserts, heavily decreasing for large packaged inserts. We describe a fast (4 h) centrifugation protocol at reduced speed allowing high virus recovery even for large and fragile lentivirus vectors. The protocols outlined in the current report should be useful for many labs interested in producing and concentrating high titer lentiviral stocks.

Citing Articles

Cracking the Code: Reprogramming the Genetic Script in Prokaryotes and Eukaryotes to Harness the Power of Noncanonical Amino Acids.

Jann C, Giofre S, Bhattacharjee R, Lemke E Chem Rev. 2024; 124(18):10281-10362.

PMID: 39120726 PMC: 11441406. DOI: 10.1021/acs.chemrev.3c00878.


Development of adenoviral vectors that transduce Purkinje cells and other cerebellar cell-types in the cerebellum of a humanized mouse model.

Kul E, Okoroafor U, Dougherty A, Palkovic L, Li H, Valino-Ramos P Mol Ther Methods Clin Dev. 2024; 32(2):101243.

PMID: 38605812 PMC: 11007541. DOI: 10.1016/j.omtm.2024.101243.


Generation of patient-derived pediatric pilocytic astrocytoma in-vitro models using SV40 large T: evaluation of a modeling workflow.

Selt F, El Damaty A, Schuhmann M, Sigaud R, Ecker J, Sievers P J Neurooncol. 2023; 165(3):467-478.

PMID: 37999877 PMC: 10752915. DOI: 10.1007/s11060-023-04500-6.


Engineering B cells with customized therapeutic responses using a synthetic circuit.

Page A, Delles M, Negre D, Costa C, Fusil F, Cosset F Mol Ther Nucleic Acids. 2023; 33:1-14.

PMID: 37359346 PMC: 10285500. DOI: 10.1016/j.omtn.2023.05.024.


A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptor.

Reichenbach P, Giordano Attianese G, Ouchen K, Cribioli E, Triboulet M, Ash S Nat Biomed Eng. 2023; 7(9):1063-1080.

PMID: 37069267 PMC: 10504085. DOI: 10.1038/s41551-023-01013-5.